News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accentia Biopharmaceuticals Announces Option Agreement With Mayo Foundation On Patented Treatment Using Intranasal Antifungals For Chronic Sinusitis



12/15/2005 12:50:02 PM

TAMPA, Fla.--(BUSINESS WIRE)--Dec. 15, 2005--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it has signed an option agreement with the Mayo Foundation for Medical Education and Research for the exclusive right to negotiate a license for a method of use for any and all antifungals other than amphotericin B applied intranasally for the treatment of chronic sinusitis, sometimes known as chronic rhinosinusitis. If unexercised, the option expires on December 6, 2006. Accentia has previously obtained a worldwide exclusive license for the method of use, utilizing the antifungal, amphotericin B, for this indication. Accentia is developing a unique formulation of amphotericin B for intranasal application for the treatment of chronic sinusitis under an Investigational New Drug Application (IND).

Read at BioSpace.com

Related News

comments powered by Disqus
   
Sinusitis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES